Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 126 results found since Jan 2013.
M174 haemophilus influenzae type b meningitis – a case of vaccine failure
Haemophilus influenzae is a pleomorphic gram-negative bacteria commonly found within the respiratory tract. Haemophilus influenzae serotype b (Hib) is a typeable (encapsulated) strain known to cause invasive disease. Hib polysaccharide-protein conjugate vaccines stimulate a highly immunogenic T-cell dependent response which has dramatically decreased the incidence of invasive disease. Here we present a case of Hib meningitis resulting in sensorineural hearing loss in an immunized infant, presumed to be secondary to vaccine failure.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: J. Yeager, E. Wisner Source Type: research
Diagnostic Vaccination in Clinical Practice
Testing the antibody response to vaccination (diagnostic vaccination) is crucial in the clinical evaluation of primary immunodeficiency diseases. Guidelines from the American Academy of Allergy, Asthma & Immunology (AAAAI) provide detailed recommendations for diagnostic vaccination with pure pneumococcal polysaccharide vaccines (PPV). However, the degree of compliance with these guidelines and the utility of the guidelines in actual practice are undescribed. To address this, we systematically evaluated diagnostic vaccination in adult patients with suspected primary immunodeficiency diseases in a single tertiary center ...
Source: Frontiers in Immunology - September 30, 2021 Category: Allergy & Immunology Source Type: research
Pediatric health care professionals ’ vaccine knowledge, awareness and attitude: a survey within the Italian Society of Pediatric Allergy and Immunology
ConclusionsOur results indicate that pHCPs ’ attitude and confidence in regards to vaccines remain suboptimal. Current COVID-19 pandemic and the rapid development of vaccines could increase vaccine hesitancy. Due to the documented pHCPs’ influence in the parental decision, educational interventions are needed to improve their level of kn owledge and counselling skills in order to address parental vaccine hesitancy and to maintain continuity of immunization services.
Source: Italian Journal of Pediatrics - September 9, 2021 Category: Pediatrics Source Type: research
Risk for Asthma at Age 4 Years Higher After Pneumonia in Infancy
Risk slightly higher after introduction of nationwide pneumococcal conjugate vaccine
Source: Pulmonary Medicine News - Doctors Lounge - September 1, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Pediatrics, Pulmonology, Allergy, Journal, Source Type: news
An Enzyme-Linked ImmunoSpot Assay (ELISPOT) to Assess Pneumovax ® Response when on Intravenous Immunoglobulin
CONCLUSION: Our pilot study suggests an optimized ELISPOT protocol has utility to assess the P23-specific antibody response after vaccination. Our ELISPOT assay seemed reliable for patients on IVIG and may help differentiate true CVID patients from those with a less stringent diagnosis while on IVIG.PMID:34391898 | DOI:10.1016/j.anai.2021.08.003
Source: Annals of Allergy, Asthma and Immunology - August 15, 2021 Category: Allergy & Immunology Authors: Neema Izadi Vijaya Knight Matthew Strand Harry R Hill Lisa K Peterson Pia J Hauk Source Type: research
An enzyme-linked immunospot assay to evaluate Pneumovax response when on intravenous immunoglobulin
Testing for common variable immunodeficiency (CVID) requires evaluation of specific antibody responses to vaccines. Current practice of evaluating pneumococcal serotype-specific immunoglobulin (Ig)G levels after Pneumovax (P23) has several limitations and is not accurate for patients already on immunoglobulin replacement. In contrast, the enzyme-linked immunospot (ELISPOT) assay can be interpreted in patients on immunoglobulin replacement as ex vivo measurement of specific antibody-secreting cells (ASCs).
Source: Annals of Allergy, Asthma and Immunology - August 12, 2021 Category: Allergy & Immunology Authors: Neema Izadi, Vijaya Knight, Matthew Strand, Harry R. Hill, Lisa K. Peterson, Pia J. Hauk Tags: Original Article Source Type: research
Sex differences in antibody responses to the 23-valent pneumococcal polysaccharide vaccination
Ann Allergy Asthma Immunol. 2021 Jul 20:S1081-1206(21)00512-3. doi: 10.1016/j.anai.2021.07.013. Online ahead of print.NO ABSTRACTPMID:34298171 | DOI:10.1016/j.anai.2021.07.013
Source: Annals of Allergy, Asthma and Immunology - July 23, 2021 Category: Allergy & Immunology Authors: Sergio E Chiarella Sarah M Jenkins Miguel A Park Roshini S Abraham Avni Y Joshi Source Type: research
Can AstraZeneca ’s Vaccine Prevent the Spread of COVID-19 Virus?
In a new—yet to be peer-reviewed—study, the pharmaceutical company AstraZeneca and its partners at the University of Oxford report that their COVID-19 shot may not only protect against disease but also help to prevent spread of the SARS-CoV-2 virus. The news was heralded by policy makers desperate to see a vaccine that can curb spread of the disease, but scientists have been a bit more cautious. If confirmed, the results would represent a breakthrough in the COVID-19 vaccine race. So far, the shots authorized or approved around the world have shown strong protection against moderate to severe disease, but haven...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Impact of immunization with pneumococcal conjugated vaccines on the aplicability of the diagnostic criteria for specific pneumococcal antibody deficiency
Diagnostic criteria for specific antibody deficiency (SAD) were established before the incorporation of pneumococcal conjugate vaccines (PCV) in immunization schedules. We evaluated the effect of PCV immunization on the applicability of these criteria.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Daniela Navarrete-Cort és, David Rodriguez-Cabezas, María Cristina Mayol, Antonia Sánchez, Aileen Ferran, Nicole Silva, Constanza Silva, Teresa Quiroga, Katia Abarca, Rodrigo Hoyos Source Type: research
Impact of Age and Region on Immune Responses to Allergy Immunotherapy
Allergy immunotherapy (AIT) can prevent allergic disease by modifying the adaptive immune system, similar to anti-pathogen vaccines, supporting the concept of AIT as an “allergy vaccination”. Some vaccines, e.g. influenza, pneumococcal pneumoniae, are administered globally with the same dose for all age groups. The aim of this study was to determine if sublingual immunotherapy (SLIT) across regions and age groups induce similar immunologic changes in IgE and Ig G4 with the goal of using the same dose and formulation worldwide.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Josephine Nolte Peterlin, Vibeke Backer, Thomas Stranzl, Veronica Hulstroem, Peter Sejer Andersen, Hendrik Nolte Source Type: research
Results of Cross-Stakeholder Qualitative Study on the Potential Utility of a Hyperimmune Globulin for the Prophylaxis/Treatment for S. Pneumoniae Infection in Vulnerable Populations
Streptococcus pneumoniae accounts for 20% to 38% of nosocomial infection, contributing to high rates of hospitalization and mortality. Approximately half of the adult population are not vaccinated with approved and commercially available S. pneumoniae vaccines and remain vulnerable to contracting pneumonia, even post vaccination. We evaluated the potential clinical utility and level of reimbursement for an anti-pneumococcal polyclonal hyperimmune globulin ?for at-risk patients in hospital and outpatient settings.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Jeffrey Gruenglas, Drew Pantello, James Mond Source Type: research
